Glycosaminoglycans modulate RANKL-induced osteoclastogenesis

Ling Ling, Sadasivam Murali, Gary S. Stein, Andre J van Wijnen, Simon M. Cool

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Skeletal integrity is tightly regulated by the activity of osteoblasts and osteoclasts that are both under the control of extracellular glycosaminoglycans (GAGs) through their interactions with endogenous growth factors and differentiation-promoting ligands. Receptor activator of NF-kappa-B ligand (RANKL), which is a tumor necrosis factor (TNF)-related protein that is critical for osteoclast formation, is produced by osteoblasts and further modulated by certain types of GAGs. Using unfractionated osteoblast-derived GAGs that reflect the complex tissue microenvironment within which osteoclasts reside, we demonstrate that these GAGs block the osteoclastogenic activity of RANKL. Furthermore, RANKL significantly reduces extracellular signal-regulated protein kinase (ERK) activity, a putative suppressor of osteoclastogenesis, but osteoblast-derived GAGs eliminate the inhibitory effects of RANKL on ERK activity. Notably, while imposing an anti-osteoclastic effect, these GAGs also enhanced the proliferation of osteoblasts. Thus, the osteoblast microenvironment is a potent source of GAGs that promote bone anabolic activities. The anti-osteoclastogenic and osteoblast-related mitogenic activities of these GAGs together may provide a key starting point for the development of selective sugar-based therapeutic compounds for the treatment of osteopenic disorders.

Original languageEnglish (US)
Pages (from-to)1222-1231
Number of pages10
JournalJournal of Cellular Biochemistry
Volume109
Issue number6
DOIs
StatePublished - Apr 15 2010
Externally publishedYes

Fingerprint

Receptor Activator of Nuclear Factor-kappa B
Glycosaminoglycans
Osteoblasts
Osteogenesis
Ligands
Osteoclasts
Growth Differentiation Factors
glycosaminoglycan receptor
Extracellular Signal-Regulated MAP Kinases
Sugars
Protein Kinases
Bone
Tumor Necrosis Factor-alpha
Tissue

Keywords

  • ERK
  • Glycosaminoglycans
  • Osteoclastogenesis
  • RANKL

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Molecular Biology

Cite this

Ling, L., Murali, S., Stein, G. S., van Wijnen, A. J., & Cool, S. M. (2010). Glycosaminoglycans modulate RANKL-induced osteoclastogenesis. Journal of Cellular Biochemistry, 109(6), 1222-1231. https://doi.org/10.1002/jcb.22506

Glycosaminoglycans modulate RANKL-induced osteoclastogenesis. / Ling, Ling; Murali, Sadasivam; Stein, Gary S.; van Wijnen, Andre J; Cool, Simon M.

In: Journal of Cellular Biochemistry, Vol. 109, No. 6, 15.04.2010, p. 1222-1231.

Research output: Contribution to journalArticle

Ling, L, Murali, S, Stein, GS, van Wijnen, AJ & Cool, SM 2010, 'Glycosaminoglycans modulate RANKL-induced osteoclastogenesis', Journal of Cellular Biochemistry, vol. 109, no. 6, pp. 1222-1231. https://doi.org/10.1002/jcb.22506
Ling L, Murali S, Stein GS, van Wijnen AJ, Cool SM. Glycosaminoglycans modulate RANKL-induced osteoclastogenesis. Journal of Cellular Biochemistry. 2010 Apr 15;109(6):1222-1231. https://doi.org/10.1002/jcb.22506
Ling, Ling ; Murali, Sadasivam ; Stein, Gary S. ; van Wijnen, Andre J ; Cool, Simon M. / Glycosaminoglycans modulate RANKL-induced osteoclastogenesis. In: Journal of Cellular Biochemistry. 2010 ; Vol. 109, No. 6. pp. 1222-1231.
@article{b90d7f0d397048afa696043fb203f13e,
title = "Glycosaminoglycans modulate RANKL-induced osteoclastogenesis",
abstract = "Skeletal integrity is tightly regulated by the activity of osteoblasts and osteoclasts that are both under the control of extracellular glycosaminoglycans (GAGs) through their interactions with endogenous growth factors and differentiation-promoting ligands. Receptor activator of NF-kappa-B ligand (RANKL), which is a tumor necrosis factor (TNF)-related protein that is critical for osteoclast formation, is produced by osteoblasts and further modulated by certain types of GAGs. Using unfractionated osteoblast-derived GAGs that reflect the complex tissue microenvironment within which osteoclasts reside, we demonstrate that these GAGs block the osteoclastogenic activity of RANKL. Furthermore, RANKL significantly reduces extracellular signal-regulated protein kinase (ERK) activity, a putative suppressor of osteoclastogenesis, but osteoblast-derived GAGs eliminate the inhibitory effects of RANKL on ERK activity. Notably, while imposing an anti-osteoclastic effect, these GAGs also enhanced the proliferation of osteoblasts. Thus, the osteoblast microenvironment is a potent source of GAGs that promote bone anabolic activities. The anti-osteoclastogenic and osteoblast-related mitogenic activities of these GAGs together may provide a key starting point for the development of selective sugar-based therapeutic compounds for the treatment of osteopenic disorders.",
keywords = "ERK, Glycosaminoglycans, Osteoclastogenesis, RANKL",
author = "Ling Ling and Sadasivam Murali and Stein, {Gary S.} and {van Wijnen}, {Andre J} and Cool, {Simon M.}",
year = "2010",
month = "4",
day = "15",
doi = "10.1002/jcb.22506",
language = "English (US)",
volume = "109",
pages = "1222--1231",
journal = "Journal of Cellular Biochemistry",
issn = "0730-2312",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - Glycosaminoglycans modulate RANKL-induced osteoclastogenesis

AU - Ling, Ling

AU - Murali, Sadasivam

AU - Stein, Gary S.

AU - van Wijnen, Andre J

AU - Cool, Simon M.

PY - 2010/4/15

Y1 - 2010/4/15

N2 - Skeletal integrity is tightly regulated by the activity of osteoblasts and osteoclasts that are both under the control of extracellular glycosaminoglycans (GAGs) through their interactions with endogenous growth factors and differentiation-promoting ligands. Receptor activator of NF-kappa-B ligand (RANKL), which is a tumor necrosis factor (TNF)-related protein that is critical for osteoclast formation, is produced by osteoblasts and further modulated by certain types of GAGs. Using unfractionated osteoblast-derived GAGs that reflect the complex tissue microenvironment within which osteoclasts reside, we demonstrate that these GAGs block the osteoclastogenic activity of RANKL. Furthermore, RANKL significantly reduces extracellular signal-regulated protein kinase (ERK) activity, a putative suppressor of osteoclastogenesis, but osteoblast-derived GAGs eliminate the inhibitory effects of RANKL on ERK activity. Notably, while imposing an anti-osteoclastic effect, these GAGs also enhanced the proliferation of osteoblasts. Thus, the osteoblast microenvironment is a potent source of GAGs that promote bone anabolic activities. The anti-osteoclastogenic and osteoblast-related mitogenic activities of these GAGs together may provide a key starting point for the development of selective sugar-based therapeutic compounds for the treatment of osteopenic disorders.

AB - Skeletal integrity is tightly regulated by the activity of osteoblasts and osteoclasts that are both under the control of extracellular glycosaminoglycans (GAGs) through their interactions with endogenous growth factors and differentiation-promoting ligands. Receptor activator of NF-kappa-B ligand (RANKL), which is a tumor necrosis factor (TNF)-related protein that is critical for osteoclast formation, is produced by osteoblasts and further modulated by certain types of GAGs. Using unfractionated osteoblast-derived GAGs that reflect the complex tissue microenvironment within which osteoclasts reside, we demonstrate that these GAGs block the osteoclastogenic activity of RANKL. Furthermore, RANKL significantly reduces extracellular signal-regulated protein kinase (ERK) activity, a putative suppressor of osteoclastogenesis, but osteoblast-derived GAGs eliminate the inhibitory effects of RANKL on ERK activity. Notably, while imposing an anti-osteoclastic effect, these GAGs also enhanced the proliferation of osteoblasts. Thus, the osteoblast microenvironment is a potent source of GAGs that promote bone anabolic activities. The anti-osteoclastogenic and osteoblast-related mitogenic activities of these GAGs together may provide a key starting point for the development of selective sugar-based therapeutic compounds for the treatment of osteopenic disorders.

KW - ERK

KW - Glycosaminoglycans

KW - Osteoclastogenesis

KW - RANKL

UR - http://www.scopus.com/inward/record.url?scp=77951756269&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951756269&partnerID=8YFLogxK

U2 - 10.1002/jcb.22506

DO - 10.1002/jcb.22506

M3 - Article

C2 - 20135643

AN - SCOPUS:77951756269

VL - 109

SP - 1222

EP - 1231

JO - Journal of Cellular Biochemistry

JF - Journal of Cellular Biochemistry

SN - 0730-2312

IS - 6

ER -